Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab in pediatric XLH
NCT02163577Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2014
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of burosumab in X-linked hypophosphatemia (XLH) (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Rickets Severity Score Total Score at Week 160, Serum Phosphorus Concentration at Week 160 and 2 more. Started Jul 2014; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT02163577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163577.